Full CoveragePfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
By Kevin Dunleavy
Top news
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
By Colin Kellaher
Pfizer Receives FDA Approval for Bleeding Disorder Treatment
By Emily Dattilo
Pfizer’s (PFE) First Gene Therapy Gets Approval for Clotting Disorder
By Damian Garde
Pfizer Stock: Pharma Giant Takes On Hemgenix At $3.5 Million A Dose
By Allison Gatlin
All coverage
FDA OKs Second Gene Therapy for Hemophilia B
By Charles Bankhead
Pfizer Gains as Gene Therapy Wins FDA Nod
By Glenn Wilkins
USFDA nod to Pfizer Beqvez for adults with Hemophilia B
By Kamal Kohli & Ruchika Sharma
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia - Pfizer (NYSE:PFE)
By Vandana Singh
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
By Annika Kim Constantino
Pfizer's gene therapy Beqvez OK'd for adults with hemophilia B by FDA
By Lindsey Shapiro
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
By Annika Kim Constantino
